ArticleFrontiers in endocrinology2025
Lobectomy vs total thyroidectomy for unilateral papillary thyroid carcinoma with ipsilateral cervical lymph node metastasis.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Interpretable machine learning for presurgical differentiation of Hürthle cell carcinoma and adenoma: a SHAP-augmented approach.Frontiers in endocrinology · 2026Article
- Personalized risk prediction of lateral lymph node metastasis in male papillary thyroid cancer: a sex-specific model leveraging central lymph node ratio.Future oncology (London, England) · 2025Article
- The relationship between the extent of extrathyroidal extension and lymph node metastasis based on propensity score matching analysis.Gland surgery · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to compare the prognosis of unilateral papillary thyroid carcinoma(PTC) patients with ipsilateral cervical lymph node metastasis(IC-LNM) under the treatment of unilateral lobectomy(uLT) vs total thyroidectomy(TT) in order to find out the optimal surgery for these patients without other clinical risk characteristics. Methods: PTC patients at Zhejiang Cancer Hospital between 2012 and 2022 were retrospectively reviewed. Additionally, a propensity score matching(PSM) was performed on patients treated with uLT or TT. Recurrence-free survival(RFS), overall survival(OS), hospitalization costs, postoperative complications, and other clinical characteristics were analyzed between the two groups. Results: Ultimately, 682 unilateral PTC patients with IC-LNM were available in the study. After PSM with possible prognostic factors(such as gender, age, primary tumor size, multifocality, extrathyroidal invasion, and T-stage), 225 pairs of patients were available. With a median of 81(5-154) months follow-up, 22 patients(9.8%) in the uLT and 12(5.3%) in the TT recurred. There were no significant differences in 5-year RFS and 5-year OS between uLT and TT groups. However, TT group was significantly correlated with higher risk of transient and permanent hypoparathyroidism, higher levothyroxine doses, longer hospital stays, and higher hospitalization costs than uLT group(p<0.05). Conclusions: Our study indicated that there were no differences in recurrence and survival between unilateral PTC patients with IC-LNM treated with uLT or TT for the primary tumor. However, uLT group had a lower risk of postoperative complications and a lower hospitalization cost than TT group. Thus, for selected unilateral PTC patients with IC-LNM without other risk features, uLT could be recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.